FFA
APGE

Farther Finance Advisors’s Apogee Therapeutics APGE Stock Holding History

Farther Finance Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51K Buy
34
+3
+10% +$270 ﹤0.01% 4848
2026
Q1 		$2.61K Sell
31
-19
-38% -$1.38K ﹤0.01% 4790
2025
Q4 		$3.77K Buy
50
+23
+85% +$1.45K ﹤0.01% 4446
2025
Q3 		$1.07K Sell
27
-33
-55% -$1.26K ﹤0.01% 4346
2025
Q2 		$2.61K Sell
60
-101
-63% -$3.84K ﹤0.01% 3609
2025
Q1 		$5.73K Buy
+161
New +$6.22K ﹤0.01% 2995

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Farther Finance Advisors's APGE Position: Q2 2026 in Review

Farther Finance Advisors increased its Apogee Therapeutics (APGE) stake by 9.7% in Q2 2026, buying an estimated $270 and bringing the position to 34 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4848.

Farther Finance Advisors first reported a position in APGE in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.73K in Q1 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Farther Finance Advisors held 34 shares of Apogee Therapeutics worth $4.51K as of Q2 2026.
  • Farther Finance Advisors bought 3 Apogee Therapeutics shares in Q2 2026, an estimated $270.
  • Apogee Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4848 holding.
  • Farther Finance Advisors first reported a position in Apogee Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Farther Finance Advisors's Apogee Therapeutics position peaked at $5.73K in Q1 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.